This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Loteprednol is a corticosteroid indicated in the treatment of pain and inflammation after cataract surgery.
- Brand Names
- Alrex, Lotemax, Zylet
- Generic Name
- Loteprednol
- DrugBank Accession Number
- DB00873
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Loteprednol (DB00873)
- Weight
- Average: 394.889
Monoisotopic: 394.154701681 - Chemical Formula
- C21H27ClO5
- Synonyms
- Loteprednol
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Acarbose. Acetohexamide The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Acetohexamide. Acetyldigitoxin The risk or severity of adverse effects can be increased when Loteprednol is combined with Acetyldigitoxin. Albiglutide The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Albiglutide. Alogliptin The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Alogliptin. Aminoglutethimide The therapeutic efficacy of Loteprednol can be decreased when used in combination with Aminoglutethimide. Bendroflumethiazide The risk or severity of electrolyte imbalance can be increased when Loteprednol is combined with Bendroflumethiazide. Benzthiazide The risk or severity of electrolyte imbalance can be increased when Loteprednol is combined with Benzthiazide. Bexagliflozin The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Bexagliflozin. Bromocriptine The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Bromocriptine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ALREX STERILE OPHTHALMIC SUSPENSION 0.2% Loteprednol (2 mg/1mL) + Benzalkonium chloride (100 mcg/1mL) Suspension / drops Ophthalmic บริษัท บอช แอนด์ ลอมบ์ (ประเทศไทย) จำกัด 2009-02-06 2020-09-23 Thailand 
LOTEMAX (STERILE OPHTHALMIC SUSPENSION 0.5%) Loteprednol (5 mg/1mL) + Benzalkonium chloride (100 mcg/1mL) Suspension / drops Ophthalmic บริษัท บอช แอนด์ ลอมบ์ (ประเทศไทย) จำกัด 2014-02-25 Not applicable Thailand ZYLET (STERILE OPHTHALMIC SUSPENSION) Loteprednol (5 MG/1ML) + Tobramycin (3.333 MG/1ML) Suspension Ophthalmic บริษัท บอช แอนด์ ลอมบ์ (ประเทศไทย) จำกัด 2012-09-25 Not applicable Thailand
Categories
- ATC Codes
- S01BA14 — Loteprednol
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androgens and derivatives
- Alternative Parents
- 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives / Carboxylic acid esters / Monocarboxylic acids and derivatives show 4 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Alkyl chloride / Alkyl halide / Androgen-skeleton show 18 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- organochlorine compound, 11beta-hydroxy steroid, 17alpha-hydroxy steroid, androstanoid, 3-oxo-Delta(1),Delta(4)-steroid, steroid acid ester (CHEBI:50848)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z8CBU6KR16
- CAS number
- 129260-79-3
- InChI Key
- YPZVAYHNBBHPTO-MXRBDKCISA-N
- InChI
- InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1
- IUPAC Name
- chloromethyl (1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1-carboxylate
- SMILES
- [H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
References
- General References
- Health Canada Approved Drug Products: Lotemax (Loteprednol) Ophthalmic Ointment [Link]
- External Links
- ChemSpider
- 8041134
- 237027
- ChEBI
- 50848
- ZINC
- ZINC000030691679
- Wikipedia
- Loteprednol
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Treatment Contact Lens Related Dry Eye 1 3 Withdrawn Treatment Bacterial Conjunctivitis / Infection Associated Blepharitis / Keratitis / Ocular Inflammation 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension / drops Ophthalmic Suspension Ophthalmic - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0336 mg/mL ALOGPS logP 2.2 ALOGPS logP 2.52 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 12.01 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 83.83 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 102.65 m3·mol-1 Chemaxon Polarizability 41.29 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at August 24, 2018 15:59 / Updated at November 30, 2023 01:44